trending Market Intelligence /marketintelligence/en/news-insights/trending/kl-cR4vPeK33YlyRByRLAA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UPDATE: Allergan shareholders approve $84B AbbVie deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

UPDATE: Allergan shareholders approve $84B AbbVie deal

Allergan PLC shareholders have approved via a vote the Irish company's $84.2 billion acquisition by AbbVie Inc.

Two separate meetings — one at the Irish High Court and another extraordinary general meeting — were held Oct. 14 to seek shareholders' approval, and more than 99% of the votes cast were in favor of the deal.

The acquisition was announced June 25 at a 45% premium to Botox-maker Allergan's closing price the day before and is expected to close in early 2020.

With the approval, the combined company would be the fifth-largest drugmaker in the world, based on combined 2018 revenue of $48.54 billion.

At the time of the deal announcement, Leerink analyst Marc Goodman said although AbbVie's bid was on the low end despite the "wounded stock," Allergan shareholders would likely be rewarded for sticking with the company as its valuation sank deeper over the course of a year.

The companies have exchanged letters with the U.S. Federal Trade Commission, but the completion is expected to occur on time, they said. Advocacy groups and unions have urged the FTC to block the acquisition.

AbbVie sought out the Allergan deal to make up for potential future losses on its rheumatoid arthritis drug Humira, the best-selling drug in the world, as it is set to see U.S. competition in 2023.

SNL Image